期刊文献+

术前^(18)F-FDG PET/CT代谢参数模型预测肝细胞癌肝移植术后复发的价值

Value of preoperative PET/CT metabolic parameter-based model in predicting the recurrence of hepatocellular carcinoma after liver transplantation
下载PDF
导出
摘要 目的探讨应用术前^(18)F-FDG PET/CT代谢参数的模型预测肝细胞癌(HCC)肝移植(LT)术后复发中的价值。方法回顾性分析了86 LT术前接受^(18)F-FDG PET/CT检查的HCC患者的临床、病理和影像学资料,并提取^(18)F-FDG PET/CT图像中的代谢参数。通过Cox回归分析筛选出与HCC患者LT术后复发相关的危险因素,将具有统计学意义的因素组合建立PET/CT代谢参数模型,同时建立米兰标准模型、加州大学旧金山分校(UCSF)标准模型和杭州标准模型。计算各模型的一致性指数(C-index)并进行比较。使用Kaplan-Meier曲线及决策曲线分析(DCA)评估不同模型判别不同HCC患者复发风险的能力和临床实用性。结果研究纳入的86例患者中,41例(47.7%)LT术后复发。术前甲胎蛋白(AFP)(P<0.001)、肿瘤代谢体积(MTV)(P=0.020)、病变总糖酵解(TLG)(P=0.016)是预测LT术后复发的危险因素。组合以上因素建立的PET/CT代谢参数模型的C-index为0.689,高于现有通用标准模型。结论结合AFP和PET/CT代谢参数的综合模型对HCC患者LT术后复发具有较高的预测价值。 Objective To explore the value of a preoperative ^(18)F-FDG PET/CT metabolic parameter-based model in predicting recurrence of hepatocellular carcinoma(HCC)after liver transplantation(LT).Methods Clinical,pathological,and ^(18)F-FDG PET/CT imaging characteristics of 86 patients with confirmed HCC before LT were retrospectively analyzed.Metabolic parameters were extracted from the ^(18)F-FDG PET/CT images.Cox regression analysis was applied to determine the risk factors associated with HCC recurrence.Statistically significant factors were all integrated to build the PET/CT metabolic parameter-based model,Milan standard model,the University of California,San Francisco standard model,and Hangzhou standard model.The concordance index(C-index)of each model was calculated and compared.Kaplan-Meier curves were plotted to reveal the discrimination ability of models.Clinical practicality of the final model was assessed by decision curve analysis(DCA).Results HCC recurred in 47.7%(41/86).Preoperative alpha-fetoprotein(AFP)level(P<0.001),metabolic tumor volume(MTV,P=0.020),and total lesion glycolysis(TLG,P=0.016)were identified as risk factors for recurrence.The PET/CT metabolic parameter-based model achieved the highest C-index of 0.689 and distinguished LT candidates with different recurrence risk better than other models based on current common criteria.Conclusion The model combining AFP and ^(18)F-FDG PET/CT metabolic parameters shows good efficacy in predicting the recurrence of HCC patients after LT.
作者 胡欣 林方增 林晓洁 文芳 王晓燕 HU Xin;LIN Fangzeng;LIN Xiaojie;WEN Fang;WANG Xiaoyan(Department of Nuclear Medicine,The First Affiliated Hospital of Sun Yat-sen University,Guangdong,510080,China)
出处 《影像诊断与介入放射学》 2023年第5期359-366,共8页 Diagnostic Imaging & Interventional Radiology
关键词 肝细胞癌 肝移植 正电子发射型计算机断层显像 无复发生存期 Hepatocellular carcinoma Liver transplantation Positron emission tomography/computed tomography Recurrence-free survival
  • 相关文献

参考文献3

二级参考文献114

  • 1Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI:10.3322/canjclin.55.2.74]. 被引量:1
  • 2Penn I. Hepatic transplantation for primary and metastatic cancersof the liver. Surgery 1991; 110: 726-734; discussion 734-735[PMID: 1656538]. 被引量:1
  • 3Zaman SN, Melia WM, Johnson RD, Portmann BC, JohnsonPJ, Williams R. Risk factors in development of hepatocellularcarcinoma in cirrhosis: prospective study of 613 patients. Lancet1985; 1: 1357-1360 [PMID: 2861313 DOI: 10.1016/S0140-6736(85)91785-4]. 被引量:1
  • 4Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: currentsurgical management. Gastroenterology 2004; 127: S248-S260[PMID: 15508091 DOI: 10.1053/j.gastro.2004.09.039]. 被引量:1
  • 5Bruix J, Sherman M. Management of hepatocellular carcinoma.Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]. 被引量:1
  • 6Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS,Waddell WR. Homotransplantation of the liver in humans. SurgGynecol Obstet 1963; 117: 659-676 [PMID: 14100514]. 被引量:1
  • 7Iwatsuki S, Starzl TE, Todo S, Gordon RD, Esquivel CO, TzakisAG, Makowka L, Marsh JW, Koneru B, Stieber A. Experiencein 1,000 liver transplants under cyclosporine-steroid therapy:a survival report. Transplant Proc 1988; 20: 498-504 [PMID:3279643]. 被引量:1
  • 8Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M,Miceli R, Mariani L. Milan criteria in liver transplantation forhepatocellular carcinoma: an evidence-based analysis of 15 yearsof experience. Liver Transpl 2011; 17 Suppl 2: S44-S57 [PMID:21695773 DOI: 10.1002/lt.22365]. 被引量:1
  • 9Iwatsuki S, Gordon RD, Shaw BW, Starzl TE. Role of livertransplantation in cancer therapy. Ann Surg 1985; 202: 401-407[PMID: 2996449 DOI: 10.1097/00000658-198510000-00001]. 被引量:1
  • 10Bismuth H, Castaing D, Ericzon BG, Otte JB, Rolles K, RingeB, Sloof M. Hepatic transplantation in Europe. First Report ofthe European Liver Transplant Registry. Lancet 1987; 2: 674-676[PMID: 2887952 DOI: 10.1016/S0140-6736(87)92453-6]. 被引量:1

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部